EMS and BD expand access to GLP-1 therapies in Brazil with semaglutide launch

BD (Becton, Dickinson and Company), a global medical technology company, and EMS, one of Brazil's leading pharmaceutical companies, have announced their collaboration to launch a semaglutide therapy in Brazil. This partnership aims to address the healthcare challenges associated with chronic diseases such as obesity and type 2 diabetes.

The launch highlights the increasing demand for GLP-1 therapies and the need for reliable delivery systems that provide safe and accurate dosing for patients. Many patients struggle with self-injection due to difficulties in ease of use and adherence to treatment, underscoring the importance of intuitive delivery solutions.

EMS's semaglutide will utilize BD's Vystra™ Injection Pen platform, known for its user-friendly design. This platform reflects BD's extensive experience in drug delivery systems, offering scalable solutions that can meet the growing demand for injectable therapies.

Patrick Jeukenne, Worldwide President of Pharmaceutical Systems at BD, stated, "BD's partnership with EMS introduces a critical treatment option backed by scalable, patient-centric delivery technology." Gabriel Sanchez, Vice President of EMS, added, "Launching our semaglutide marks an important step in expanding access to advanced metabolic therapies in Brazil."

BD is a leading medical technology company focused on advancing health through innovation, operating globally with over 60,000 employees. EMS has more than 60 years of experience in the pharmaceutical industry and continues to invest in research and development to improve therapies for obesity and type 2 diabetes.